Ron Lanton Ron Lanton

Medicaid's Next Gene Therapy Move: What International Developers Should Know

CMS plans to expand its Medicaid Cell and Gene Therapy Access Model beyond sickle cell disease. Lanton Strategies International examines what the proposed expansion could mean for international biotechnology companies planning U.S. launches, reimbursement agreements and commercial partnerships.

CMS is preparing to expand its approach to gene therapy reimbursement. For international developers, the changes could affect U.S. launch planning, commercial agreements, and investment decisions.

By Ron Lanton
President, Lanton Strategies International B.V.

For companies developing gene therapies, FDA approval is only part of the challenge. The commercial question is whether insurers will cover the treatment, how much they will pay, and whether patients can receive it at qualified treatment centers.

On October 27, 2026, the Centers for Medicare & Medicaid Services (CMS) announced plans to expand its Cell and Gene Therapy (CGT) Access Model beyond sickle cell disease. The agency intends to invite manufacturers of additional therapies into a program that negotiates outcomes-based payment arrangements on behalf of participating state Medicaid programs.

CMS also plans to allow reimbursement negotiations to begin sooner after FDA approval, potentially giving manufacturers greater clarity as they prepare for commercial launch. For international biotechnology companies, this could influence U.S. market entry, licensing negotiations, and financial projections.

What CMS Is Changing

The CGT Access Model allows CMS to negotiate payment agreements with manufacturers rather than requiring each participating Medicaid program to negotiate separately. These agreements can include upfront discounts and additional rebates when treatments fail to achieve agreed clinical outcomes.

The initial program focuses on sickle cell disease. CMS reports that 32 states, the District of Columbia, and Puerto Rico are participating, representing approximately 84% of Medicaid beneficiaries with the condition.

Its first evaluation found that centralized negotiations reduced administrative burdens and improved states' negotiating leverage. Those findings are encouraging, although they do not yet establish whether the model will improve long-term patient outcomes or reduce overall treatment spending.

The planned expansion could make the model relevant to a broader group of manufacturers. CMS expects to release a new application process in the coming months, including opportunities for companies with therapies already approved by the FDA.

What This Means for Commercial Planning

Earlier reimbursement negotiations may help companies better understand the financial assumptions supporting a U.S. launch. That could be particularly valuable for smaller biotechnology developers negotiating with investors or pharmaceutical partners.

There are also financial responsibilities to consider.

Outcomes-based agreements may require manufacturers to provide additional rebates when patients do not achieve specified clinical results. Those obligations can affect revenue forecasts, milestone payments, and the economics of licensing or commercialization agreements.

Long-term outcomes reporting presents another challenge. Some gene therapies require years of patient monitoring, during which individuals may change providers, relocate, or move between insurance plans. Manufacturers need to understand how outcomes will be measured, who will collect the data, and how financial obligations will be managed over time.

Federal Medicaid drug rebate rules, including Best Price requirements, also need to be considered when structuring these arrangements. Existing value-based purchasing flexibilities may be available, but their application depends on the terms of the agreement.

For companies entering the U.S. market, these issues should be addressed during commercial planning rather than after a reimbursement contract has been negotiated.

Medicaid Does Not Resolve Every Access Question

The significance of the CMS model will depend on the disease being treated and the insurance coverage of the affected patient population.

Medicaid covers a substantial share of patients with sickle cell disease. For other rare conditions, commercial insurance may account for a larger portion of the market.

A CMS-negotiated agreement could improve Medicaid access without resolving reimbursement questions involving commercial insurers.

Manufacturers must also consider whether qualified treatment centers are available. Gene therapies frequently require specialized facilities, trained personnel, and extended patient monitoring. Favorable reimbursement terms alone will not ensure patients can receive treatment.

International companies evaluating U.S. commercialization partnerships should consider reimbursement, patient access, and treatment delivery together.

What the Midterm Elections Mean

The November 2026 midterm elections introduce another consideration. Democrats will control both chambers of Congress beginning in January 2027, creating opportunities for greater oversight of federal healthcare policy and renewed debate over Medicaid financing.

The election does not change CMS's announced plans or automatically alter the CGT Access Model. The program remains voluntary, and CMS continues to administer it under existing authority.

For manufacturers, the practical response is to follow congressional developments while continuing to prepare for the reimbursement framework currently in place. Future funding decisions and policy changes may affect the broader Medicaid environment, but the election itself has not changed the model's terms.

The Decisions Ahead for International Developers

The expansion could provide international gene therapy developers with another opportunity to address U.S. reimbursement earlier in the commercialization process.

Its value will depend on which therapies qualify, how CMS structures negotiations, and whether participating manufacturers can manage the associated financial and reporting obligations.

Companies considering U.S. licensing arrangements, commercial partnerships, or investment should examine how Medicaid reimbursement could affect projected revenues, contractual responsibilities, and launch timing. They should also assess commercial insurance coverage and the availability of treatment facilities.

The forthcoming CMS application process will provide more information about the expansion. Until then, manufacturers should avoid assuming that eligibility or favorable reimbursement terms are guaranteed.

For international developers, the larger commercial question remains straightforward. Regulatory approval creates an opportunity to enter the U.S. market, but reimbursement and patient access determine how much of that opportunity can be realized.

Addressing those questions early can improve commercial planning and help companies negotiate partnerships with a clearer understanding of the U.S. healthcare market.

About Lanton Strategies International

Lanton Strategies International B.V. advises pharmaceutical, biotechnology, and healthcare companies on U.S. and European market access, reimbursement policy, international business strategy, and commercial planning.

This article is intended for general business and policy information and does not constitute legal advice.

Read More